Loading...
  • serum
  • Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. (ox.ac.uk)
  • These 32 individuals and 64 matched controls were analyzed for serum antibodies indicative of past infection with Chlamydia trachomatis, Neisseria gonorrhoeae, cytomegalovirus, Epstein-Barr virus, and herpes simplex virus type 2. (ox.ac.uk)
  • In a healthy individual, the total kappa to lambda ratio is roughly 2:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. (wikipedia.org)
  • For instance, in the second LDH-C4 primate trial that had negative results, all of the immunized macaque monkeys developed high antibody titers against LDH-C4 in serum, but antibodies against LDH-C4 were not found in the monkeys' vaginal fluids. (wikipedia.org)
  • adult
  • SL-401) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older, in both treatment-na├»ve and previously-treated populations. (pipelinereview.com)
  • Fragments
  • To improve the imaging agent, multiple versions of humanized PSCA antibody fragments were created and subsequently tested for their abilities to image in vivo using micro-PET, with the goal to eventually detect distant metastases. (dtic.mil)
  • lymphoma
  • Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia. (wikipedia.org)
  • citation needed] In preclinical studies with human lymphomas and myelomas, both naked Milatuzumab and the Milatuzumab conjugated with doxorubicin, an antibody-drug conjugate or ADC, have demonstrated anti-lymphoma activity in-vivo. (wikipedia.org)
  • A Phase I study of Milatuzumab, a humanized anti-CD74 antibody, and Veltuzumab, a humanized anti-CD20 antibody, in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. (wikipedia.org)
  • Additionally
  • Additionally, a blood test showing high levels of the antibody ganglionic nicotenic acetylcholine receptor (gAChr) occur in about 50% of patients with AAG (seropositive AAG). (wikipedia.org)
  • Immunoglobulins
  • Immunoproliferative disorders, also known as immunoproliferative diseases or immunoproliferative neoplasms, are disorders of the immune system that are characterized by the abnormal proliferation of the primary cells of the immune system, which includes B cells, T cells and natural killer (NK) cells, or by the excessive production of immunoglobulins (also known as antibodies). (wikipedia.org)
  • patients
  • Patients may have antibodies of more than one type, and CSAab and SyAab may be present together with anti-INAab, especially in paraneoplastic AIE. (scielo.br)
  • The seronegative patients (those without detectable gAChR levels) are theorized to have one or more different antibodies responsible for the autonomic dysfunction. (wikipedia.org)
  • date=16 June 2010 A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma. (wikipedia.org)
  • typically
  • Pubmed ID: 12417508 Somatostatinomas involving the gastrointestinal tract are extremely rare neoplasms that typically present with indolent, nonspecific symptoms in the absence of systemic neuroendocrine manifestations that characterize the somatostatinoma syndrome. (jove.com)
  • drug
  • Milatuzumab-Doxorubicin (IMMU-110 / hLL1-dox) Clinical Trials - ADC Review / Journal of Antibody-drug Conjugates Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma - News Medical and Immunomedics Press Release. (wikipedia.org)
  • methods
  • It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine. (google.com)